This is the text extract for Provisional agreement with AstraZeneca to amend terms of listing of various pharmaceuticals in the Pharmaceutical Schedule, browse documents here.

---

31 July 2007

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

Consultation on provisional agreement with AstraZeneca to amend terms of listing of various pharmaceuticals in the Pharmaceutical Schedule

PHARMAC and AstraZeneca Limited have entered into a provisional agreement to amend the terms of listing of quetiapine (Seroquel), sodium chloride for injection (AstraZeneca) and propofol (Diprivan) in the Pharmaceutical Schedule. Key aspects of this proposal are as follows: · The price and subsidy of quetiapine (Seroquel) tablets would be reduced in Section B and in Part II of Section H of the Pharmaceutical Schedule with effect from 1 October 2007 as follows (ex-manufacturer, excluding GST):

Pharmaceutical Brand Form Strength Pack size Current price & subsidy New price & subsidy before rebate $46.20 $92.40 $158.78 $267.12

Quetiapine Quetiapine Quetiapine Quetiapine

Seroquel Seroquel Seroquel Seroquel

Tablet Tablet Tablet Tablet

25 mg 100 mg 200 mg 300 mg

60 60 60 60

$55.00 $110.00 $189.00 $318.00

· · · ·

Seroquel would be listed in Section B of the Pharmaceutical Schedule without the requirement for endorsement for subsidy from 1 October 2007. Seroquel tablets dispensed in the community and in DHB hospitals would be subject to a confidential rebate from 1 October 2008. Seroquel would have protection from delisting and subsidy reduction until 30 September 2010. The price of sodium chloride inj 0.9% 50x 10 mL and 50x 5 mL (AstraZeneca) listed in Part II of Section H of the Pharmaceutical Schedule would be reduced with effect from 1 January 2008 as follows (ex-manufacturer, excluding GST):

Pharmaceutical Sodium chloride Sodium chloride Brand AstraZeneca AstraZeneca Form Ampoule (injection) Ampoule (injection) Strength 0.9% per 5 mL 0.9% per 10 mL Pack Size 50 50 Current price $11.50 $11.50 New price $8.77 $8.77

A140129 - T07-019

---

·

Sodium chloride inj 0.9% 50x 10 mL and 50x 5 mL (AstraZeneca) purchased by DHB hospitals would be subject to a rebate for the period 1 January 2008 to the expiry of Hospital Supply Status (HSS) on 30 June 2009. Propofol with EDTA (Diprivan) would be listed in Part II of Section H of the Pharmaceutical Schedule at the following prices (ex-manufacturer, excluding GST) from 1 January 2008 to the expiry of Hospital Supply Status (HSS) on 30 June 2009:

Pharmaceutical Propofol with EDTA Propofol with EDTA Propofol with EDTA Propofol with EDTA Propofol with EDTA Brand Diprivan Diprivan Diprivan Diprivan Diprivan Form Vial (Injection) Vial (Injection) Vial (Injection) Pre-filled syringe Pre-filled syringe Strength 1%, 20 ml 1%, 50 ml 1%, 100 ml 1%, 50 ml 2%, 50 ml Pack size 5 1 1 1 1 Current price $25.00 $15.00 $19.00 $25.00 $30 New price $17.02 $9.26 $15.46 $14.19 $15.43

·

·

Following expiry of HSS status, propofol with EDTA (Diprivan) would be listed in Part II of Section H of the Pharmaceutical Schedule at the new prices specified in the above table from 1 July 2009 until at least 30 June 2010 (ex-manufacturer, excluding GST).

If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC, care of Andrew Davies (andrew.davies@pharmac.govt.nz or by fax or post) by 5:00 pm, 16 August 2007. All comments submitted by this date will be considered. Yours sincerely

Andrew Davies Procurement Initiatives Manager

A140129 - T07-019

2